

CURRICULUM VITAE

September 24, 2011

NAME:

Dennis R. Hoffman

TITLE:

Senior Research Scientist

DATE OF BIRTH:

09/07/51

MARITAL STATUS:

Divorced, two children

CITIZENSHIP:

United States Citizen

HOME ADDRESS:

7601 Churchill Way, #1636

Dallas, Texas 75251

Telephone: (214) 392-6781

OFFICE ADDRESS:

Retina Foundation of the Southwest (RFSW)

9900 North Central Expressway, #400

Dallas, Texas 75231

Telephone:(214)363-3911 ext.125

Fax:(214) 363-4538

E-mail: dhoffman@retinafoundation.org

EDUCATION:

B.S., 1973, Chemistry, Jamestown College

Jamestown, ND

Ph.D., 1979, Biochemistry, University of North Dakota,

Grand Forks, ND

RESEARCH EXPERIENCE:

1979 - 1980

Postdoctoral fellow, Department of Biochemistry,

University of North Dakota, Grand Forks, ND

1980 - 1984

Research Associate-National Cancer Institute

Carcinogenesis Training Program through the

University of Tennessee, Biology Division, Oak Ridge

National Laboratory, Oak Ridge, TN

1984 - 1987

Chilton postdoctoral fellow, Departments of

Biochemistry and Obstetrics-Gynecology, The

University of Texas Southwestern Medical Center at

Dallas, TX (UTSWMC)

1987 - 1989

Assistant Instructor, Department of Pediatrics, Center

for Human Nutrition, UTSWMC

1989 - 1991

Instructor, Department of Pediatrics, UTSWMC

1991 - 1997

Research Scientist, RFSW, Dallas, TX

1991 – present

Director, Alice B. Pearson Visual Biochemistry

Laboratory

1991 - 2000

Adjunct Instructor, Department of Pediatrics,

UTSWMC

2002 - 2007

Radiation Safety Officer, RFSW

1997 - present

Senior Research Scientist, RFSW

1999 - 2009

Assistant Research Director, RFSW

2009- present

Chief Research Officer, RFSW

2010 – present

Adjunct Assistant Professor, Department of

Ophthalmology, UTSWMC

PROFESSIONAL SOCIETIES:

American Society for Biochemistry and Molecular Biology - Member
Sigma Xi - Member;
American Oil Chemists' Society - Member
Association for Research in Vision and Ophthalmology - Member
International Society for the Study of Fatty Acids and Lipids (ISSFAL)-Member
American Society for Nutritional Sciences - Member
American Society for Clinical Nutrition – Member
Journal of Oleo Science -Editorial Advisory Board Member

JOURNAL REFEREE:

<i>Lipids</i>	<i>Biochimica et Biophysica Acta</i>
<i>Journal of Lipid Research</i>	<i>American Journal of Clinical Nutrition</i>
<i>Metabolism</i>	<i>Invest. Ophthalmol. Vis. Sci.</i>
<i>Experimental Eye Research</i>	<i>Journal of Clinical Investigation</i>
<i>British J. of Ophthalmology</i>	<i>European J Clinical Nutrition</i>
<i>Early Human Development</i>	<i>Proc. Natl Acad Sci.</i>
<i>European J Clinical Nutrition</i>	<i>Pediatric Research</i>
<i>Molecular Vision</i>	<i>Pediatrics</i>

GRANT REVIEWER:

Thrasher Research Fund
Foundation Fighting Blindness
National Eye Institute

PATENTS:

BABY-FOOD COMPOSITIONS ENHANCING VISUAL ACUITY AND METHODS THEREFOR; Richard C. Theuer, Eileen E. Birch, Dennis R. Hoffman, Gerald E. Shaul, Terry L. Rockin, Mary Beth Cool, Virginia A. San Fanandre, , Robert A. Harvey; Beech-Nut Nutrition Corp. and Retina Foundation of the Southwest; United States Patent Office; #7,141,266, November 28, 2006.

METHOD OF ENHANCING COGNITIVE ABILITY IN INFANT FED DHA CONTAINING BABY-FOOD COMPOSITIONS; Eileen E. Birch, Mary Beth Cool, Robert A. Harve,; Dennis R. Hoffman, Terry L. Rockin, Virginia A. San Fanandre, Gerald E. Shaul, Richard C. Theuer, Beech-Nut Nutrition Corp. and Retina Foundation of the Southwest; United States Patent Office #7,413,759 B2; August 19, 2008.

PATENT APPLICATION (patent not approved):

USE OF DOCOSAHEXAENOIC ACID AND ARACHIDONIC ACID TO ENHANCE THE VISUAL DEVELOPMENT OF TERM INFANTS BREAST-FED UP TO THE AGE OF SIX MONTHS; Dennis Robert Hoffman, Eileen Elizabeth Birch, Julia Anne Boettcher, Deborah Ann Schade; Retina Foundation of the Southwest and Mead Johnson Nutritionals; United States Patent Office; #20040048926, submitted March 11, 2004.

PEER-REVIEWED PUBLICATIONS:

1. **Hoffman DR, Skurdal DN and Cornatzer WE:** Viral stimulation of choline phosphotransferase in spleen microsomes, Lipids **10**:829-834, 1975.
2. **Hoffman DR, Cornatzer WE and Duerre JA:** Relationship between tissue levels of S-adenosylhomocysteine and transmethylation reactions, Can. J. Biochem. **57**:56-65, 1979.
3. **Hoffman DR, Uthus EO and Cornatzer WE:** Effect of diet on choline phosphotransferase, phosphatidylethanolamine methyltransferase and phosphatidyl dimethyl ethanolamine methyltransferase in liver microsomes, Lipids **15**:439-446, 1980.
4. **Hoffman DR, Marion DW, Cornatzer WE and Duerre JA:** Adenosylmethionine and adenosylhomocysteine metabolism in isolated rat liver: Effects of L-methionine, L-homocysteine, and adenosine, J.Biol.Chem. **255**:10822-10827, 1980.
5. **Hoffman DR, Haning JA and Cornatzer WE:** Microsomal phosphatidylethanolamine methyltransferase: Effect of altered S-adenosylmethionine: S-adenosyl- homocysteine ratios in rat liver, Internatl. J. Biochem. **13**:745-748, 1981.
6. **Hoffman DR, Haning JA and Cornatzer WE:** Effects of alloxan diabetes on phosphatidylcholine biosynthetic enzymes, Proc. Soc. Exptl. Biol. Med. **167**:143-146, 1981.
7. **Hoffman DR and Cornatzer WE:** Microsomal phosphatidylethanolamine methyltransferase: Some physical and kinetic properties, Lipids **16**:533-540, 1981.
8. **Hoffman DR, Haning JA and Cornatzer WE:** Microsomal phosphatidylethanolamine methyltransferase: Inhibition by S-adenosylhomocysteine, Lipids **16**:561-567, 1981.
9. **Hoffman DR, Haning JA and Cornatzer WE:** Effect of a methyl-deficient diet on rat liver phosphatidylcholine biosynthesis, Can. J. Biochem. **59**:543-550, 1981.
10. **Hoffman DR and Huberman E:** The control of phospholipid methylation by phorbol diesters in differentiating human myeloid HL-60 leukemia cells, Carcinogenesis **3**:875-880, 1982.
11. **Berdel WE, Grainer E, Fink U, Stavrou D, Reichert A, Rastetter J, Hoffman DR and Snyder F:** Cytotoxicity of alkyllysophospholipid derivatives and low alkyl-cleavage enzyme activities in rat brain tumor cells. Cancer Res. **43**:541-545, 1983.
12. **Hoffman DR, Haning JA and Cornatzer WE:** Effects of diethanolamine on phosphatidylcholine biosynthetic enzymes of rat liver microsomes, Internatl. J. Biochem. **15**:367-371, 1983.
13. **Cornatzer WE, Hoffman DR and Haning JA:** The effect of embryological development on phosphatidylethanolamine methyltransferase, phosphatidyl-dimethylethanolamine methyltransferase and choline phosphotransferase of rabbit liver microsomes, Lipids **19**:1-4, 1984.
14. **Cornatzer WE, Hoffman DR and Haning JA:** The effect of hyper and hypothyroidism, hypophysectomy and adrenalectomy on phosphatidylethanolamine methyltransferase, phosphatidyl-dimethyl-

- ethanolamine methyltransferase, and choline phosphotransferase of rat liver microsomes, *Internatl. J. Biochem.* **16**:567-570, 1984.
15. **Hoffman DR**, Hajdu J and Snyder F: Cytotoxicity of platelet activating factor and related alkyl-phospholipid analogs in human leukemia cells, polymorphonuclear neutrophils and skin fibroblasts. *Blood* **63**:545-552, 1984.
 16. **Hoffman DR**, Stanley JD and Snyder F: Cytotoxicity of ether-linked phytanyl phospholipid analogs and related derivatives in human HL-60 leukemia cells and polymorphonuclear neutrophils. *Res Commun Chem Pathol Pharmacol* **44**:293-306, 1984.
 17. **Hoffman DR**, Haning JA and Cornatzer WE: Effect of Friend virus infection on phosphatidylcholine biosynthetic enzymes in mouse spleen microsomes. *Life Sci.* **34**:2621-2626, 1984.
 18. Billah MM, DiRenzo GC, Ban C, Truong CT, **Hoffman DR**, Anceschi MM, Bleasdale JE and Johnston JM: Platelet-activating factor metabolism in human amnion and the response of this tissue to extracellular platelet activating factor. *Prostaglandins* **30**:841-850, 1985.
 19. **Hoffman DR**, Truong CT and Johnston JM: The role of platelet-activating factor in human fetal lung maturation. *Amer J Obstet Gynecol.* **155**:70-75, 1986.
 20. **Hoffman DR**, Truong CT and Johnston JM: Metabolism and function of platelet-activating factor in rabbit fetal lung development. *Biochim Biophys Acta* **879**:88-96, 1986.
 21. **Hoffman DR**, Hoffman LH and Snyder F: Cytotoxicity and metabolism of alkyl phospholipid analogs in neoplastic cells. *Cancer Res.* **46**:5803-5809, 1986.
 22. Snyder F, Record M, Smith Z, Blank ML and **Hoffman DR**: Selective cytotoxic action of ether-lipid analogs of PAF: Mechanistic studies related to their metabolism, subcellular localization, and effects on cellular transport systems, *Aktuel. Onkol.* **34**:19-26, 1987.
 23. Maki N, **Hoffman DR** and Johnston JM: PAF (platelet-activating factor) acetylhydrolase activities in maternal, fetal, and newborn rabbit plasma during pregnancy and lactation, *Proc. Natl. Acad. Sci., U.S.A.*, **85**:728-732, 1988.
 24. **Hoffman DR**, Bateman MK and Johnston JM: Synthesis of platelet-activating factor by 1-alkyl-2-acetyl-glycerol: CDP-choline cholinephosphotransferase in developing fetal rabbit lung, *Lipids*, **23**, 96-100, 1988.
 25. **Hoffman DR**, White RG, Angle MJ and Johnston JM: Platelet-activating factor induces glycogen degradation in fetal rabbit lung *in utero*, *J. Biol. Chem.*, **263**, 9316-9319, 1988.
 26. **Hoffman DR**, Romero R and Johnston JM: Detection of platelet-activating factor in amniotic fluid of complicated pregnancies. *Am. J. Obstet. Gynecol.* **162**:525-528, 1990.
 27. Uauy R, Birch D, Birch E, Tyson J and **Hoffman DR**: Effect of omega-3 fatty acids on retinal function of very low birth weight neonates. *Pediatric Res.*, **28**,485-492, 1990.
 28. McCoshen JA, **Hoffman DR**, Kredentser JV, Araneda C and Johnston JM: The role of fetal membranes in regulating production, transport and metabolism of prostaglandin E₂ during labor. *Am. J. Obstet. Gynecol.*, **163**:1632-1640, 1990.

29. Zhu Y-P, **Hoffman DR**, Hwang S-B, Miyaura S, and Johnston JM: Prolongation of parturition in the rat following treatment with platelet-activating factor (PAF) receptor antagonists. *Biology of Reproduction*, **44**:39-42, 1991.
30. Bourbon JR, **Hoffman DR**, and Johnston JM: Effects of platelet-activating factor on the fetal rat lung *in vivo* and *in vitro*. *Exp. Lung Res.*, **17**:789-801, 1991.
31. Birch DG, Birch EE, **Hoffman DR**, and Uauy RD: Retinal development in very-low-birth-weight infants fed diets differing in omega-3 fatty acids. *Invest. Ophthalmol. Vis. Sci.*, **33**:2365-2376, 1992.
32. **Hoffman DR**, Thomas VL, and Snyder F: Inhibition of cellular transport systems by alkyl phospholipid analogs in HL-60 human leukemia cells. *Biochim. Biophys. Acta* **1127**:74-80, 1992.
33. Treen M, Uauy R, Jameson D, Thomas VL, and **Hoffman DR**: Effect of docosahexaenoic acid (DHA) on membrane fluidity and function in Y-79 retinoblastoma cells. *Arch. Biochem. Biophys.*, **294**:564-570, 1992.
34. Birch EE, Birch DG, **Hoffman DR**, and Uauy R: Dietary essential fatty acid supply and visual acuity development. *Invest. Ophthalmol. Vis. Sci.*, **33**:3242-3253, 1992.
35. **Hoffman DR**, and Uauy R: Essentiality of dietary omega-3 fatty acids for premature infants: plasma and red blood cell fatty acid composition. *Lipids*, **27**:886-895, 1992.
36. Moya FR, **Hoffman DR**, Zhao B, and Johnston JM: Platelet-activating factor in surfactant preparations. *Lancet* **341**:858-860, 1993.
37. Birch E, Birch D, **Hoffman D**, Hale L, Everett M, and Uauy R: Breast-feeding and optimal visual development. *J. Pediatr. Ophthalmol. Strabismus*, **30**:33-38, 1993.
38. **Hoffman DR**, Uauy R, and Birch DG: Red blood cell fatty acid levels in patients with autosomal dominant retinitis pigmentosa. *Exper. Eye Res.*, **57**:359-368, 1993.
39. **Hoffman DR**, Favour S, Uauy R, Rosenfeld CR, and Magness RR: Distribution of unsaturated fatty acids in phospholipids of arteries from nonpregnant, pregnant and fetal sheep. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **49**:901-914, 1993.
40. Uauy R, **Hoffman DR**, Birch EE, Birch DG, Jameson DM, and Tyson J: Safety and efficacy of omega-3 fatty acids in the nutrition of very low birth weight infants: soy oil and marine oil supplementation of formula. *J. Pediatr.* **124**:612-620, 1994.
41. **Hoffman DR** and Birch DG: Docosahexaenoic acid in red blood cells of patients with X-linked retinitis pigmentosa. *Invest. Ophthalmol. Vis. Sci.* **36**: 1009-1018, 1995.
42. **Hoffman DR**, Uauy R, and Birch DG: Metabolism of omega-3 fatty acids in patients with autosomal dominant retinitis pigmentosa. *Exp. Eye Res.* **60**: 279-289, 1995.
43. Buraczynska M, Wu W, Fujita R, Buraczynska K, Phelps E, Andreasson S, Bennitt J, Birch DG, Fishman GA, **Hoffman DR**, Jacobson SG, Musarella MA, Sieving PA, and Swaroop A: Spectrum of mutations in 20% of families with X-linked retinitis pigmentosa. *Am. J. Hum. Genet.* **61**: 1287-1292, 1997.
44. Birch EE, **Hoffman DR**, Uauy R, Birch DG, and Prestidge C: Visual acuity and the essentiality of docosahexaenoic acid and arachidonic acid in the diet of term

- infants. *Pediatr. Res.* **44**: 201-209, 1998.
45. Gieser L, Fujita R, Goring HHH, Ott J, **Hoffman DR**, Cideciyan AV, Birch DG, Jacobson SG, and Swaroop A: A novel locus (RP24) for X-linked retinitis pigmentosa maps to Xq 26-27. *Am. J. Hum. Genet.* **63**: 1439-1447, 1998.
 46. **Hoffman DR**, Birch EE, Birch DG, and Uauy R: Fatty acid profile of buccal cheek cell phospholipids as an index for dietary intake of docosahexaenoic acid in preterm infants. *Lipids* **34**: 337-342, 1999.
 47. Birch EE, Garfield S, **Hoffman DR**, Uauy R: A randomized controlled trial of early dietary supply of long chain polyunsaturated fatty acids and mental development in term infants. *Dev. Med. Child Neurol.* **42**: 174-181, 2000.
 48. **Hoffman DR**, Birch EB, Birch DG, Uauy R, Castañeda YS, Lapus MG, Wheaton DH: Impact of early dietary intake and blood lipid composition of long-chain polyunsaturated fatty acids on later visual development. *J. Pediatr. Gastroenterol. Nutr.* **31**: 540-53, 2000.
 49. Guevara-Fujita M, Fahrner S, Buraczynska K, Cook J, Wheaton D, Cortes F, Vicencio C, Pena M, Fishman GA, Mintz-Hittner H, Birch D, **Hoffman D**, Mears AJ, Fujita R, and Swaroop A: Five novel RPGR mutations in families with X-linked retinitis pigmentosa. *Human Mutation*, **396**: Online, 2000.
 50. **Hoffman DR**, DeMar JC, Heird WC, Birch DG, and Anderson RE: Impaired synthesis of docosahexaenoic acid (DHA) in patients with X-linked retinitis pigmentosa (XLRP). *J. Lipid Res.* **42**: 1395-1401, 2001.
 51. Birch EE, **Hoffman DR**, Castañeda YS, Fawcett SL, Birch DG, and Uauy RD: A randomized controlled trial of long-chain polyunsaturated fatty acid supplementation of formula in term infants after weaning at 6 wk of age. *Am. J. Clin. Nutr.* **75**: 570-580, 2001.
 52. Birch DG, Hood DC, Locke KG, **Hoffman DR**, and Tzekov RT: Quantitative ERG measures of phototransduction in cone and rod photoreceptors: normal aging, progression with disease, and test-retest variability. *Arch. Ophthalmol.*, **1120**: 1045-1051, 2002.
 53. Breuer DK, Yashar BM, Filippova E, Hiriyan S, Lyons RH, Mears AJ, Asaye B, Acar C, Vervoort R, Wright AF, Musarella MA, Wheeler P, MacDonald I, Iannaccone A, Birch D, **Hoffman DR**, Fishman GA, Heckenlively JR, Jacobson SG, Sieving PA, and Swaroop AA. Comprehensive mutation analysis of RP2 and RPGR in a North American cohort of families with X-linked retinitis pigmentosa. *Am. J. Human Genetics*, **70**: 1545-1554, 2002.
 54. Rojas CV, Martinez JI, **Hoffman DR**, and Uauy R. Gene expression analysis in human fetal retinal explants treated with docosahexaenoic acid. *Invest. Ophthalm. Vis. Sci.*, **44**:3170-3177, 2003.
 55. **Hoffman DR**, Birch EE, Castañeda YS, Fawcett SL, Wheaton DH, Birch DG, and Uauy R: Visual function in breast-fed term infants weaned at 4 and 6 months to formula with or without long-chain polyunsaturates: A randomized clinical trial. *J. Pediatr.* **142**:669-677, 2003.
 56. Wheaton DH, **Hoffman DR**, Locke KG, Watkins RB, and Birch DG. Biological safety assessment of docosahexaenoic acid (DHA) supplementation in X-linked retinitis pigmentosa (XLRP). *Arch. Ophthalmol.* **121**:1269-1278, 2003.
 57. **Hoffman DR**, Locke KG, Wheaton DH, Fish GE, Spencer, R. and Birch DG. A

- randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. *Amer. J. Ophthalmol.* **137**: 704-718, 2004.
58. **Hoffman DR**, Theuer RC, Castañeda YS, Wheaton DKH, Morale SE, Wiedemann LE, and Birch EE: Maturation of visual acuity is accelerated in breast-fed term infants fed baby food containing DHA-enriched egg yolk. *Journal of Nutrition* **134**: 2307-2313, 2004.
 59. Morale SE, **Hoffman DR**, Castañeda YS, Wheaton DH, Burns RA, and Birch EE: Duration of long-chain polyunsaturated fatty acids availability in the diet and visual acuity. *Early Human Development* **81**: 197-203, 2005.
 60. Birch EE, Castañeda, YS, Wheaton, DH, Birch, DG, Uauy, RD, and **Hoffman DR**: Visual maturation of term infants fed LCP-supplemented or control formula for 12 months. *American Journal of Clinical Nutrition* **81**: 871-879, 2005
 61. Makrides M, Gibson RA, Udell T, Ried K, and the International LCPUFA Investigators. Supplementation of infant formula with long-chain polyunsaturated fatty acids does not influence the growth of term infants. *American Journal of Clinical Nutrition.* **81**: 1094-1101, 2005.
 62. Udell T, Gibson RA, Makrides M, and the PUFA Study Group. The effect of alpha-linolenic acid (ALA) and linoleic acid (LA) on the growth and development of formula-fed infants: a systematic review and meta-analysis of randomized controlled trials. *Lipids* **40**: 1-11, 2005.
 63. **Hoffman DR**, Wheaton DKH, James KJ, Tuazon M, Diersen-Schade DA, Harris CL, Stolz S, and Berseth CL. Docosahexaenoic acid in red blood cells of term infants receiving two levels of long-chain polyunsaturated fatty acids. *J.Pediatr. Gastroenterol. Nutr.* **42**: 287-292, 2006.
 64. Lloyd-Still JD, Powers CA, **Hoffman DR**, Boyd-Trull K, Lester LA, Benisek DC, and Arterburn LM. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. *Nutrition* **22**: 36-46, 2006.
 65. Birch EE, Garfield S, Castañeda YS, Wheaton DKH, Uauy R, **Hoffman DR**. Visual acuity and cognitive outcomes at 4 years of age in a double-blind, randomized trial of long-chain polyunsaturated fatty acid-supplemented infant formula. *Early Human Development* **83**:279-284, 2007.
 66. **Hoffman D**, Ziegler E, Mitmesser SH, Harris CL, Diersen-Schade DA. Soy-based infant formula supplemented with DHA and ARA supports growth and increases circulating levels of these fatty acids in infants. *Lipids* **43**:29-35, 2007.
 67. Scalabrin DM, Johnston WH, **Hoffman DR**, P'pool VL, Harris CL, Mitmesser SH. Growth and tolerance of healthy term infants receiving hydrolyzed infant formulas supplemented with Lactobacillus rhamnosus GG: randomized, double-blind, controlled trial. *Clin. Pediatr.* **48**:734-744, 2009.
 68. Drover JR, **Hoffman DR**, Castañeda YS, Morale SE, Birch EE. Three randomized controlled trials of early long-chain polyunsaturated fatty acid supplementation on means-end problem solving in 9-month-olds. *Child Development.* **80**:1376-1384, 2009.
 69. **Hoffman DR**, Boettcher JA, Diersen-Schade DA. Toward optimizing vision and cognition in term infants by dietary docosahexaenoic and arachidonic acid

supplementation: A review of randomized controlled trials. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 81:151-158, 2009.

70. Birch EE, Carlson SE, **Hoffman DR**, Fitzgerald-Gustafson KM, Fu VLN, Drover JR, Castañeda YS, Minns L, Wheaton DKH, Mundy D, Marunycz J, Diersen-Schade DA. The DIAMOND (DHA Intake And Measurement Of Neural Development) Study: a double-masked, randomized controlled clinical trial of the maturation of infant visual acuity as a function of the dietary level of docosahexaenoic acid. Am J Clin Nutr, 91:848-859, 2010.
71. Drover JR, **Hoffman DR**, Castañeda YS, Morale SE, Garfield S, Wheaton DH, Birch EE. Cognitive function in 18-month-old term infants of the DIAMOND study: a randomized, controlled clinical trial with multiple dietary levels of docosahexaenoic acid. Early Hum Devel. 87:223-230, 2011.
72. Webb KD, Birch DG, **Hoffman DR**, Patel H, Daiger SP, Bowne SJ, Sullivan LS, Wheaton DKH. Assessment of Everyday Visual Tasks in Carriers of X-linked Retinitis Pigmentosa: Use of the Visual Activities and Low Luminance Questionnaires. (submitted).

REVIEWS, BOOK CHAPTERS, and INVITED PAPERS:

1. Johnston JM and **Hoffman DR**: The regulation of arachidonic acid release in parturition. In: Enzymes of Lipid Metabolism (L Freysz, H Dreyfus, R Massarelli and S Gatt, eds) Plenum Press (New York), pp 633-645, 1986.
2. **Hoffman DR** and Johnston JM: Platelet-activating factor metabolism in fetal rabbit lung development. In: New Horizons in Platelet Activating Factor Research (M Lee and C Winslow, eds) John Wiley and Sons Ltd (Sussex, England), pp. 51-55, 1987.
3. Johnston JM, Bleasdale JE and **Hoffman DR**: Functions of PAF in fetal lung maturation and parturition. In: Platelet-Activating Factor and Related Lipid Mediators (F Snyder, ed) Plenum Press (New York), pp. 375-402, 1987.
4. Uauy R, Treen, M, and **Hoffman DR**: Essential fatty acid metabolism and requirements during development. Seminars in Perinatology 13:118-130, 1989.
5. Johnston JM, Maki N, Angle MJ, and **Hoffman DR**: Regulation of the arachidonic acid cascade and PAF metabolism in reproductive tissues. In: Eicosanoids in Reproduction (M. Mitchell, ed), CRC Press, Boca Raton, FL, pp. 5-37, 1990.
6. Uauy R., Treen M, and **Hoffman DR**: Essential fatty acid metabolism and requirements for the low birth weight neonate. In: Advances On Infant Nutrition, Vol.3, (Ballabriga, A. ed.) UNIASA-EDDA, Grenada, pp. 153-180, 1990.
7. Uauy R and **Hoffman DR**: Essential fatty acid requirements for normal eye and brain development. Seminars in Perinatology, 15:449-455, 1991.
8. Uauy R, Birch D, Birch E, Tyson J, and **Hoffman D**: Are omega-3 fatty acids required for normal eye and brain development of the very low birth weight infant? In: Recent Advances in Infant Feeding, (B.Koletzko, ed.) Verlag, New York, 13-21, 1992.
9. Uauy R, Birch DG, Birch EE, and **Hoffman DR**: Essential fatty acid requirements for normal visual and neural development. In: Human Growth: Basic and Clinical Aspects. (Hernandez M, and Argente J., eds.) Elsevier Sci. Publ., New York, pp. 197-203, 1992.

10. Uauy R, Birch D, Birch E, **Hoffman D**, and Tyson J: Effect of dietary essential ω -3 fatty acids on retinal and brain development in premature infants, In: Essential Fatty Acids and Eicosanoids (A. Sinclair, R. Gibson, eds.) American Oil Chemists' Society, Champaign, IL, pp. 197-202, 1993.
11. **Hoffman DR**, Birch EE, Birch DG and Uauy RD: Effects of supplementation with ω 3 long-chain polyunsaturated fatty acids on retinal and cortical development in premature infants. Am. J. Clin. Nutr., **57**:807S-812S, 1993.
12. Uauy R, Birch DG, Birch EE, **Hoffman D** and Tyson J: Visual and brain development in infants as a function of essential fatty acid supply provided by the early diet. In: Lipids, Learning, and the Brain: Fats in Infant Formula (J Dobbing & JD Benson, eds.) Ross Laboratories (Columbus, OH) pp. 215-232, 1993.
13. **Hoffman DR**: Visual development in the neonate. Clinic Talk, **10**:4-5, 1994.
14. Uauy-Dagach R, Birch EE, Birch DG, and **Hoffman DR**: Significance of ω 3 fatty acids for retinal and brain development of preterm and term infants. In: Fatty Acids and Lipids: Biological Aspects. World Rev. Nutr. Diet (Galli C, Simopoulos AP, Tremoli E, eds.) Karger, Basel, vol. **75**: 52-62, 1994.
15. Uauy R, Birch DG, **Hoffman DR**, and Birch EE: Omega-3 fatty acids: essential nutrients for optimal retinal and brain development. In: Proc. Sci. Conf. Omega-3 Fatty Acids in Nutrition, Vascular Biology, and Medicine, (H.J. Pownall, A.A. Spector, eds.) American Heart Assoc., Dallas, TX, pp.33-46, 1994.
16. Uauy-Daguch R, Mena P, and **Hoffman DR**: Essential fatty acid metabolism and requirements for LBW infants. Acta Paediatrica, **S405**: 78-85, 1994.
17. **Hoffman DR**, Uauy R, and Birch DG: Docosahexaenoic acid abnormalities in red blood cells of patients with retinitis pigmentosa. In: Degenerative Diseases of the Retina (RE Anderson, MM LaVail, and JG Hollyfield, eds.) Plenum Publ., New York, 1995; 385-393.
18. Uauy R, Peirano P, **Hoffman D**, Mena P, Birch D, and Birch E: Role of essential fatty acids in the function of the developing nervous system. Lipids, **31**, S167-176, 1996.
19. **Hoffman DR**, Birch EE, Birch DG and Uauy R: Dietary long-chain polyunsaturates (LCPs) for preterm and term infants? controversies in visual function outcomes. In: Major Controversies in Infant Nutrition, International Congress and Symposium Series 215 (TJ David, ed.) Royal Society of Medicine Press, London, UK, pp. 45-55, 1996.
20. Uauy R, Peirano P, Mena P, **Hoffman D**, Birch D, and Birch E: LCPUFA requirements for preterm infants: Neurophysiological Studies. In: Recent Developments in Infant Nutrition (JG Bindels, AC Goedhart and HKA Visser, eds.) Kluwer Academic Publishers, Great Britain, pp.182-201, 1996.
21. Locke KG, **Hoffman DR**, Wheaton DH, and Birch DG: Description of ongoing trial with fatty acid supplementation in X-linked retinitis pigmentosa. J. Ophthalm. Photog. **19**: 27-31, 1997.
22. Uauy R, Mena P, and **Hoffman D**: Nutrition diet, and infant development: long-chain polyunsaturated fatty acids in infant neurodevelopment. In Clinical Trials in Infant Nutrition (Perman JA and Rey J, eds.) Nestle Nutrition Workshop Series, Vol. **40**, Lippincott-Raven Publishers, Philadelphia, PA, pp. 153-180, 1997.
23. **Hoffman DR** and Birch DG: Retinitis pigmentosa and lipid metabolism.

- International Society for the Study of Fatty Acids and Lipids Newsletter*, **4**: 2-7, 1997.
24. **Hoffman DR** and Birch DG: Omega-3 fatty acid status in patients with retinitis pigmentosa. *World Rev. Nutr. Diet.* **83**: 52-60, 1998.
 25. **Hoffman DR**: Fatty acids and visual dysfunction. In: *Fatty Acids in Foods and Their Health Implications*, (C.K. Chow, ed.) Mercel Dekker, New York, pp. 817-842, 2000.
 26. Uauy R and **Hoffman DR**: Essential fat requirements of preterm infants. *Am. J. Clin. Nutr.* **71**: 245S-250S, 2000.
 27. Uauy R, **Hoffman DR**, Peirano P, Birch DG, and Birch EB: Essential fatty acids in visual and brain development. *Lipids* **36**: 885-895, 2001.
 28. Breuer DK, Affer M, Andreasson S, Birch DG, Fishman GA, Heckenlively JR, Hiriyanna S, **Hoffman DR**, Jacobson SG, Mears AJ, Musarella MA, Redolfi E, Sieving PA, Wright AF, Yashar BM, Zucchi I, and Swaroop A: X-linked retinitis pigmentosa: current status. In: *New Insights Into Retinal Degenerative Diseases*, (RE Anderson, MM LaVail, and JG Hollyfield, eds.) Kluwer Academic/Plenum Publ., New York, 11-22, 2001.
 29. Uauy R, **Hoffman DR**, Mena P, Llanos A, Birch EE: Term infant studies of DHA and ARA supplementation on neurodevelopment: results of randomized controlled trials. *J. Pediatrics* **143**: S17-S25, 2003.
 30. **Hoffman DR**: LCPUFA levels for breastfeeding and weaning infants: visual acuity outcomes. *Pediatric Perspectives Newsletter*, **2**: series 5, 2004.
 31. **Hoffman DR**: Maturation of visual acuity of full-term infants in dependent on duration of dietary long-chain polyunsaturated fatty acid supply. *Pediatric Perspectives Newsletter*, **5**: series 2, 2005.
 32. **Hoffman DR**: The association between DHA and ARA levels in commercial formulas and blood lipids in healthy term infants. *Pediatric Perspectives Newsletter*, **6**: series 3, 2007.

ABSTRACTS:

1. **Hoffman DR**, Skurdal DN and Cornatzer WE: Effects of viral infection on phosphatidyl choline biosynthesis. *Fed. Proc.* **34**:933, 1975.
2. **Hoffman DR** and Cornatzer WE: Phosphatidyl ethanolamine methyltransferase activities in liver microsomes. *Proc. North Dakota Acad. Sci.* **30**:21, 1976.
3. Cornatzer WE, **Hoffman DR** and Skurdal DN: Viral stimulation of choline phosphotransferase in spleen microsomes during production of malignancy. In: *Cancer Enzymology*, J. Schultz and F. Ahmad, eds. Academic Press, New York, p.336, 1976.
4. **Hoffman DR** and Cornatzer WE: Activity of phosphatidyl ethanolamine methyltransferase (PEMT), S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) levels in liver microsomes. *Fed. Proc.* **37**:1833, 1978.
5. **Hoffman DR**, Uthus EO and Cornatzer WE: The effect of diet on choline phosphotransferase (CPT), phosphatidylethanolamine methyltransferase (PEMT) and phosphatidyl dimethyl-ethanolamine methyltransferase (PDMEMT) in liver

- microsomes. *Fed. Proc.* **38**:775, 1979.
6. **Hoffman DR** and Cornatzer WE: Effects of a methyl group depleting diet on rat liver phosphatidyl choline biosynthesis. *Fed. Proc.* **39**:1125, 1980.
 7. Marion DW, Quick DP, Briske-Anderson M and **Hoffman DR**: Metabolism of adenosylmethionine and adenosylhomocysteine in isolated rat liver. *Fed. Proc.* **39**:1902, 1980.
 8. **Hoffman DR** and Cornatzer WE: Microsomal phosphatidylethanolamine methyltransferase. *Fed. Proc.* **39**:1994, 1980.
 9. Cornatzer WE, **Hoffman DR** and Haning JA: Effect of hormone states, drugs, and embryological development on phosphatidylethanolamine methylation. *Fed. Proc.* **41**:543, 1982.
 10. **Hoffman DR** and Huberman E: Induction of phospholipid methylation by phorbol diesters in human myeloid leukemia cells (HL-60). *Fed. Proc.* **41**:911, 1982.
 11. Berdel WE, Grainer, E, Fink U, Stavrou D, Reichert A, Rastetter, J, **Hoffman DR** and Snyder F: Investigations into the correlation of the cytotoxic effect of alkyllysophospholipids on brain tumor cells of rats and their low content of alkyl-cleavage enzyme. *Onkologie* **6**:262, 1982.
 12. **Hoffman DR** and Snyder F: Selective cytotoxicity and metabolism of analogs of platelet activating factor in normal and leukemic cells. *Fed. Proc.* **43**:1459, 1984.
 13. **Hoffman DR**, Troung CT and Johnston JM: Production and function of platelet-activating factor in human fetal lung maturation. *Fed. Proc.* **44**:1203, 1985.
 14. **Hoffman DR**, Truong CT and Johnston JM: The role of platelet-activating factor in fetal rabbit lung development. *Proc. of the First Sandoz PAF Conference: New Horizons in Platelet Activating Factor Research*, 1985.
 15. Johnston JM and **Hoffman DR**: The regulation of arachidonic acid release and human parturition. *Proc. Seminars on Enzymes of Lipid Metabolism*, Strasbourg, France, 1985.
 16. **Hoffman DR** and Johnston JM: Platelet activating factor: a possible communication between fetal lung maturation and the initiation of parturition. *Proc. Society for Gynecological Investigation*, p. 79, 1986.
 17. **Hoffman DR**, Bateman MK and Johnston JM: Enzymatic biosynthesis of PAF in developing rabbit lung. *Proc. of the Second International Conference on Platelet Activating Factor*, Gatlinburg, TN. p. 124, 1986.
 18. Record M, **Hoffman DR** and Snyder F: Comparative subcellular distribution of platelet activating factor (PAF) and its antitumor methoxy Analog in HL-60 Cells. *Proc. Am. Assoc. Cancer Res.* **27**:14, 1986.
 19. **Hoffman DR** and Johnston JM: Platelet-activating factor metabolism during maturation of fetal rabbit lung. *Fed. Proc.* **45**:1531, 1986.
 20. Maki N, **Hoffman DR** and Johnston JM: PAF (platelet-activating factor) acetylhydrolase activities in maternal, fetal, and newborn rabbit plasma during pregnancy and lactation. *Proc. Society for Gynecological Investigation*, p.220, 1988.
 21. **Hoffman DR**, White RG, Angle MJ, Maki N and Johnston JM: Induction of glycogenolysis in fetal rabbit lung by platelet-activating factor. *FASEB Journal* **2**: A1377, 1988.
 22. **Hoffman DR**, Uauy R, Mize C, and Grundy S: Fatty acid (FA) composition of

- plasma cholesterol esters (CE) and RBC phosphatidylethanolamine (PE) in infants fed defined diets from birth to 1 year. *FASEB Journal*, **3**:A944, 1989.
23. **Hoffman DR**, Romero R, McGarry M, and Johnston JM: Characterization of platelet-activating factor (PAF) in amniotic fluid and the concentration of PAF in complicated pregnancies. *Proc. Society for Gynecological Investigation*, p.288, 1989.
 24. McCoshen JA, Kredentser JV, **Hoffman DR**, Odowichuk C, and Johnston JM: Metabolism of amniotic prostaglandin E₂ by amniochorion plus decidua during labor. *Proc. Society for Gynecological Investigation* p. 252, 1989.
 25. **Hoffman DR**, Favour S, Rosenfeld CR, Uauy R and Magness RR: Distribution of prostanoid precursors in phospholipids of arteries from non-pregnant, pregnant, and fetal sheep. *Proc. Society for Gynecological Investigation*, p.229, 1989.
 26. Treen M, **Hoffman D**, Jameson D and Uauy R: Effect of dietary essential fatty acids (EFA) on membrane properties of intact RBCs in VLBW neonates. *Proc. Society for Pediatric Research*, **25**:298A, 1989.
 27. Uauy R, Mize C, **Hoffman D** and Grundy S: Effect of lipid composition of the early diet on plasma lipoprotein cholesterol regulation in infants. *Proc. Am. Oil Chemists' Soc. (INFORM)*, **1**:280, 1990.
 28. Uauy R, Birch D, Birch E, Tyson J and **Hoffman D**: Are omega-3 fatty acids essential for eye and brain development in the human? *Proc. Am. Oil Chemists' Society (INFORM)*, **1**:306, 1990.
 29. Kaufman, TM, **Hoffman DR** and Mahony L: Developmental changes in lipid composition of cardiac sarcoplasmic reticulum. *Pediatric Research*, **27**:21A, 1990.
 30. Treen M, **Hoffman DR** and Uauy R: Effect of dietary omega-3 fatty acids on plasma and tissue lipids in very low birth weight neonates. *Pediatric Research*, **27**:292A, 1990.
 31. Uauy R, Birch D, Birch E and **Hoffman DR**: Effect of dietary omega-3 fatty acids (FA) of eye and brain development in very low birth weight neonates in *Health Effects of ω -3 Polyunsaturated Fatty Acids in Seafoods*. *World Rev Nutr Diet*. (Simopoulos AP, Kifer RR, Martin RE and Barlow SM, eds.) Karger, Basel, vol. **66**, 506-507, 1991.
 32. Treen M, **Hoffman DR**, Jameson D, and Uauy R: Effect of docosahexaenoic acid (DHA) on membrane fluidity and function in Y-79 retinoblastoma cells. *Pediatric Research*, **29**:54A, 1991.
 33. **Hoffman DR**, Uauy R, and Birch DG: Omega-3 fatty acids in autosomal dominant retinitis pigmentosa. *Invest. Ophthalmol. Vis. Sci.*, **32**:703, 1991.
 34. Mize C, **Hoffman DR**, and Uauy R: Effects of long-term controlled dietary fatty acid (FA) on plasma, red blood cell (RBC), & cheek cell long-chain fatty acid species from birth to 1 year. *Pediatric Research*, **29**:108A, 1991.
 35. Birch DG, Birch EE, **Hoffman DR** and Uauy R: Effects of dietary omega-3 fatty acids on rod ERG function in very-low-birth-weight neonates. *Noninvasive Assessment of the Visual System*, **1**:32-35, 1991.
 36. Uauy R, Birch DG, Birch EE and **Hoffman DR**: Are essential fatty acids required for normal visual and neural development? *Vlth International Congress of*

- Auxology*, Madrid, Spain, 1991.
37. Uauy R, Treen M, **Hoffman DR** and Jameson D. Effect of docosahexaenoic acid (DHA) on membrane properties and function in retinal cells. 32nd International Congress on Biochemistry, Granada, Spain, 1991.
 38. Birch E, Birch D, **Hoffman D**, Hale L, Everett M, and Uauy R. Breast-feeding and optimal visual development. Amer. Acad. Pediatr. Ophthalmol. Strabismus, 1992.
 39. Uauy R, Birch D, Birch E, **Hoffman D**, and Tyson J: Effect of dietary essential fatty acids on visual and brain development in premature infants. International Essential Fatty Acids Congress, Adelaide, Australia, 1992.
 40. **Hoffman DR**, Uauy R, Birch DG, and Birch EE: Essentiality of dietary docosahexaenoic acid (DHA) for optimal visual maturation in preterm infants: plasma and red blood cell (RBC) fatty acid profiles. Invest. Ophthalmol. Vis. Sci., **33**:1185, 1992.
 41. Moya F, Zhao B, **Hoffman DR**, and Johnston JM: Platelet-activating factor (PAF) and PAF-acetylhydrolase (PAF-AH) in surfactant preparations and in tracheal fluid (TF) on infants with respiratory distress syndrome (RDS). Pediatric Res. **31**:318A, 1992.
 42. Uauy R, Birch E, Birch D, and **Hoffman D**: Significance of ω -3 essential fatty acids (FA) supplied by breast milk (BM) for visual maturation of fullterm infants. Pediatric Res. **31**:296A, 1992.
 43. Uauy-Dagach R, Birch DG, Birch EE, **Hoffman DR**, and Tyson JE: Impact of ω -3 fatty acid deficiency on the development of visual function in very low birth weight infants. J. Cellular Biochemistry, **16B**: 259, 1992.
 44. **Hoffman D**, Birch EE, Birch DG, and Uauy R: Cheek cell docosahexaenoic acid (DHA) correlates with dietary fat intake and visual function. FASEB J., **7**:A63, 1993.
 45. Uauy R, Birch E, Birch D, and **Hoffman D**: Omega-3 fatty acids for retinal and brain development of preterm and term infants. Proc. International Society for the Study of Fatty Acids and Lipids, Lugano, Switzerland, July 1-3, 1993.
 46. **Hoffman DR** and Birch DG: Docosahexaenoic acid (DHA) content in red blood cells from patients with X-linked retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci., **35**:2161, 1994.
 47. Uauy R, Birch DG, **Hoffman DR**, and Birch EE: Omega-3 fatty acids: essential nutrients for optimal retinal and brain development. Proc. Sci. Conf. Omega-3 Fatty Acids in Nutrition, Vascular Biology, and Medicine, American Heart Assoc. Houston, TX, April, 1994.
 48. **Hoffman DR**, Uauy R, and Birch DG: Docosahexaenoic acid abnormalities in red blood cells of retinitis pigmentosa (RP) patients. International Symposium on Retinal Degenerations, Jerusalem, Israel, November, 1994.
 49. **Hoffman DR** and Hoffman LH: Explant cultures as a model for early human retinal development. Invest. Ophthalmol. Vis. Sci. **36**: S58, 1995.
 50. **Hoffman DR**, Uauy R, and Birch DG: Reduced levels of docosahexaenoic acid in red blood cells of patients with X-linked retinitis pigmentosa. Second International Congress of the International Society for the Study of Fatty Acids and Lipids, Washington, DC, June, 1995.
 51. **Hoffman DR**: Major controversies in infant nutrition: LCP and visual function.

- Milupa Symposium, London, October, 1995.
52. Birch EE, **Hoffman DR**, Birch DG, Uauy R, Bane M, Castañeda Y, and Prestidge C: Visual acuity development of term infants fed ω 3 long chain polyunsaturated fatty acid (LCPUFA) supplemented formula. Non-Invasive Assessment of the Visual System, Santa Fe, NM, February 1996.
 53. **Hoffman DR**, Birch EE, Birch DG, Uauy R, Castañeda YC, and Wheaton D: Red blood cell (RBC) fatty acid profiles in term infants fed formulas enriched with long-chain polyunsaturates (LCP). Invest. Ophthalmol. Vis. Sci. **37**: S802. 1996.
 54. Birch EE, Birch DG, **Hoffman DR**, Uauy R, Bane MC, Castañeda YC, Wheaton D, and Prestidge C: Visual maturation of term infants fed ω 3 long chain polyunsaturated fatty acid (LCPUFA) supplemented formula. Invest. Ophthalmol. Vis. Sci. **37**: S1112, 1996.
 55. Forsythe P, Fujita R, Buraczynska M, **Hoffman D**, Jacobson S, Sieving P, and Swaroop A: Genetic analysis of the X-linked retinitis pigmentosa locus RP3: Invest. Ophthalmol. Vis. Sci. **37**: S1123, 1996.
 56. **Hoffman DR**, Birch EE, Birch DG, and Uauy R: Visual function and blood lipid docosahexaenoic acid (DHA) in infants receiving ω 3 long-chain PUFA. American Oil Chemists' Society Conference on PUFA in Infant Nutrition: Consensus and Controversies. Barcelona, Spain, November, 1996.
 57. Mena P, Nieto S, **Hoffman D**, Gil A, and Uauy R: Red blood cell (RBC) fatty acid composition in preterm infants fed human milk or formula with different long-chain polyunsaturated fatty acid (LCPUFA) composition. American Oil Chemists' Society Conference on PUFA in Infant Nutrition: Consensus and Controversies. Barcelona, Spain, November, 1996.
 58. Swaroop A, Buraczynska M, Wu W, Chen C, Buraczynska K, Falls T, Phelps E, Andreasson S, Fishman, GA, **Hoffman D**, Jacobson SG, Sieving PA, and Fujita R.: RPGR mutations account for ~15% of X-linked retinitis pigmentosa: Invest. Ophthalm. Vis. Sci. **38**: S679, 1997.
 59. **Hoffman DR**, Wheaton DH, Locke K, and Birch DG: Rod ERG function and erythrocyte docosahexaenoic acid (DHA) in X-linked retinitis pigmentosa (XLRP). Invest. Ophthalm. Vis. Sci. **38**: S797, 1997.
 60. Locke K, Birch DG, and **Hoffman DR**: Correlation of rod photoreceptor ERG function and blood lipid docosahexaenoic acid (DHA) in X-linked retinitis pigmentosa (XLRP). Eric K. Fernstrom Symposium, Lund, Sweden, June, 1997.
 61. Swaroop A, Buraczynska M, Yan D, Gieser L, Wu W, Swain P, **Hoffman D**, Fishman G, Jacobson S, Andreasson S, Sieving P, and Fujita R: Genetic and biochemical defects in X-linked retinitis pigmentosa. Eric K. Fernstrom Symposium, Lund, Sweden, June, 1997.
 62. **Hoffman DR** and Birch DG: Omega-3 fatty acid status in patients with retinitis pigmentosa. International Conference on "Reintroduction of Omega-3 Fatty Acids into the Food Supply in Land-Based Animal Food Products" Washington, D.C., September 18-19, 1997.
 63. Locke KG, Birch EE, **Hoffman DR**, Uauy R and Birch DG: Effect of dietary DHA on retinal development in healthy full-term infants. Invest. Ophthalmol. Vis. Sci. **39**: S829, 1998.
 64. Fujita R, Buracznska M, Yan D, Wu W, Chen C, Breuer D, Buraczynska K,

- Fahrner S, Guefara-Fujita M, Gieser L, Cook J, Chada M, Chandrupatla H, Andreasson S, Fishman GA, **Hoffman DR**, Jacobson SG, Musarell M, Sieving PA, Thompson DA and Swaroop A: In search of RPGR mutations in X-linked retinitis pigmentosa: evidence of novel exonic sequences and analysis of the promoter. *Invest. Ophthalmol. Vis. Sci.* **39**: S297, 1998.
65. **Hoffman DR**, Wheaton DH, Locke K, and Birch DG: Docosahexaenoic acid (DHA) in red blood cells and electroretinographic (ERG) function in carrier heterozygotes of X-linked retinitis pigmentosa (XLRP). *Invest. Ophthalmol. Vis. Sci.* **39**: S725, 1998.
66. Wheaton DH, **Hoffman DR**, Birch DG, Fujita M, Fahrner S, Fujita R and Swaroop A: Family history of X-linked retinitis pigmentosa (XLRP) in two unrelated families and coordination of mutation analysis of the RPGR gene. *J. Genetic Counseling.* **7**: 485, 1998.
67. **Hoffman DR**, Wheaton DH, Lapus MG, Kirchoff KE, and Birch DG: Biological safety of docosahexaenoic acid (DHA) supplementation in patients with X-linked retinitis pigmentosa. *Invest. Ophthalmol. Vis. Sci.* **40**: S930, 1999.
68. Wheaton DH, **Hoffman DR**, Locke KG, Fujita M, Fujita R, and Swaroop A: Phenotypic characterization in two families X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations. *Invest. Ophthalmol. Vis. Sci.* **41**: S192, 2000.
69. **Hoffman DR** and DeMar JC: Assessment of docosahexaenoic acid (DHA) biosynthesis in patients with X-linked retinitis pigmentosa. *Invest. Ophthalmol. Vis. Sci.* **41**: S199, 2000.
70. **Hoffman DR**: Essentiality of Omega-3 Fatty Acids in Infant Development. *Institute of Food Technologists*, June 14, Dallas, TX , p. 197, 2000.
71. **Hoffman DR**, DeMar JC, Birch DG, Heird WC, Anderson RE: Impaired synthesis of docosahexaenoic acid (DHA) in patients with X-linked retinitis pigmentosa (XLRP). *4th International Congress of the International Society for the Study of Fatty Acids and Lipids (ISSFAL)*, p.135, 2000.
72. Rojas C, **Hoffman D**, Martinez J, and Uauy R: Effect of DHA on gene expression in human fetal retinal explants. *PUFA in Maternal and Child Health*, September, p. 38, 2000.
73. Uauy R, **Hoffman D**, Peirano P, and Birch E: PUFA and infant visual and mental development. *PUFA in Maternal and Child Health*, September, p. 44, 2000.
74. **Hoffman DR**, Birch EE, Castañeda YS, Fawcett SL, Birch DG, and Uauy R: Dietary docosahexaenoic acid (DHA) and visual maturation in the post-weaning term infant. *Invest. Ophthalmol. Vis. Sci.* **42**: S122, 2001.
75. Lloyd-Still JD, Powers CA, **Hoffman DR**, Boyd-Trull K, Arterburn LM, Benisek DC, and Lester LA: Blood and tissue fatty acids after docosahexaenoic acid supplementation in cystic fibrosis. *Pediatric Pulmonology* **22**: S263, 2001.
76. Rojas C, **Hoffman D**, Martinez J, and Uauy R: Effect of DHA on gene expression in human fetal retinal explants. *Lipids* **36**: 1072, 2001.
77. Powers CA, Lloyd-Still JD, **Hoffman DR**, Arterburn LM, Benisek DC, and Lester LA: Lipid soluble antioxidant status during supplementation with algal docosahexaenoic acid triglyceride in CF. *J. Cystic Fibrosis* Abstracts of the 24th European CF Conference, 133, 2001.
78. Lloyd-Still JD, Powers CA, **Hoffman DR**, Arterburn LM, Benisek DC, and Lester

- LA: Bioavailability and safety of an algal docosahexaenoic acid (DHA) triglyceride in cystic fibrosis (CF). *Pediatric Res.* **49**: 455A, 2001.
79. **Hoffman DR**, Birch EB, Castañeda YS, Fawcett SL, Wheaton DH, Birch DG, and Uauy R: Post-weaning supply of docosahexaenoic acid (DHA) improves visual maturation in breast-fed term infants. *FASEB J.* **16**: A663, 2002.
 80. Wheaton DH, **Hoffman DR**, Locke KG, Watkins, RB, and Birch DG: Safety assessment of docosahexaenoic acid (DHA) supplementation in a 4-year randomized clinical trial in X-linked retinitis pigmentosa (XLRP). *Invest. Ophthalmol. Vis. Sci.*, **43**: E-Abstract 2413, 2002.
 81. Locke KG, Fish GE, Wheaton DH, Birch DG, and **Hoffman DR**: Fundus appearance in X-linked retinitis pigmentosa (XLRP) over a 4-year-interval. *Invest. Ophthalmol. Vis. Sci.*, **43**: E-Abstract 1171, 2002.
 82. **Hoffman DR**, Locke KG, Wheaton DH, Fish GE, Watkins RB, and Birch DG: Fatty acid profiles of blood lipids from patients with X-linked retinitis pigmentosa (XLRP) supplemented with docosahexaenoic acid (DHA) for four years. *Invest. Ophthalmol. Vis. Sci.*, **43**: E-Abstract 2412, 2002.
 83. Birch DG, Hood DC, Locke KG, **Hoffman DR**, and Tzekov RT. Normal aging, progression with disease, and test-retest variability in ERG measures of cone and rod phototransduction. *Invest. Ophthalmol. Vis. Sci.*, **43**: E-Abstract 1770, 2002.
 84. **Hoffman DR**, Birch EE, Castañeda YS, Garfield S, Wheaton DH, and Birch DG: Maturation of visual and mental function in 18-month old infants receiving dietary docosahexaenoic acid (DHA) \pm arachidonic acid (ARA). *FASEB J.*, **17**:A727-8, 2003.
 85. **Hoffman DR**, Wheaton DH, Locke KG, Fish GE, and Birch DG: Four -year outcomes from a randomized clinical trial of docosahexaenoic acid (DHA) supplementation in X-linked retinitis pigmentosa (XLRP). *Invest. Ophthalmol. Vis. Sci.*, **44**: E-abstract 4851, 2003.
 86. Birch DG, Locke KG, Wheaton DH, Fish GE, and **Hoffman DR**: Dietary nutrients and yearly rates of decline in retinal function in patients with X-linked retinitis pigmentosa (XLRP). *Invest. Ophthalmol. Vis. Sci.*, **44**: E-abstract 545, 2003.
 87. Wheaton DH, Castañeda YS, **Hoffman DR**, Birch DG, and Birch EE: Biosafety of docosahexaenoic acid (DHA)/arachidonic acid (ARA) enriched infant formula fed for 9 months. *J. Amer. College Nutr.*, **22**:469, 2003.
 88. **Hoffman DR**, Theuer RC, Castañeda YS, Wheaton DH, Morale SE, Wiedemann LE, and Birch EE: Maturation of visual acuity in breast-fed term infants weaned to baby food containing DHA-enriched egg yolk. *J Amer Coll Nutr*, **22**:468, 2003.
 89. Morale SE, **Hoffman DR**, Castañeda YS, Wheaton DH, Burns RA, and Birch EE: Duration of LCPUFA availability in the diet and visual acuity at 12 months. *J. Amer. College Nutr.*, **22**: 469, 2003.
 90. **Hoffman DR**, Garfield S, Morale SE, Bosworth RG, Castañeda YS, Wheaton DKH, Theuer, RC, and Birch EE: Visual and neural development of breast-fed infants receiving docosahexaenoic acid (DHA)-enriched baby food: a randomized clinical trial. *Invest. Ophthalmol. Vis. Sci.*; **45**: E-Abstract 3510, 2004.
 91. Wheaton DKH , Birch DG, Locke KG, Swaroop A, Yashar B, Haag Branham K, Bowne SJ, Sullivan LS, Daiger SP, and **Hoffman DR**: Clinical characterization of

- disease severity and progression in X-linked retinitis pigmentosa (XLRP) associated with RPGR mutations. Invest. Ophthalmol. Vis. Sci **45**: E-Abstract 5160, 2004.
92. Blessinger BJ, Figueroa-Colon R, Diersen-Schade DA, **Hoffman DR**, Harris CL, and Ziegler EE: Different levels of docosahexaenoic acid (DHA) formula affect red blood cell DHA levels in term infants. Pediatr Res. **56**(4):670 (abstract) 2004.
 93. Figueroa-Colon R, Diersen-Schade D, **Hoffman DR**, Harris CL, and Ziegler EE: Do docosahexaenoic acid (DHA) and arachidonic acid (ARA) levels in the formula have an effect on red blood cell DHA and ARA levels of term infants? J Parenteral and Enteral Nutrition **29**(1):S28-S29 (abstract) 2005.
 94. **Hoffman DR**, and Wheaton DKH: Red blood cell levels of docosahexaenoic acid (DHA) during aging. Invest. Ophthalmol. Vis. Sci. **47**: E-Abstract 2104, 2006.
 95. Wheaton DKH, Kimberling WJ, Jensen ML, Tuazon M, Stier BD and **Hoffman DR**: Blood docosahexaenoic acid (DHA) levels in individuals with genotypically-defined Usher Syndrome. Invest. Ophthalmol. Vis. Sci. **47**: E-Abstract 4604, 2006.
 96. Diersen-Schade, DA, Ziegler EE, Stolz SI, Harris CL and **Hoffman DR**: Soy-based infant formula supplemented with ARA and DHA supports Normal Growth in Term Infants. 7th Congress of the International Society for the Study of Fatty Acids & Lipids, Cairns, Australia, P109, Page 25, July, 2006.
 97. **Hoffman DR**, Locke KG, Wheaton DKH, Fish GE, Spencer R and Birch DG: Can DHA Supplementation Slow the Loss of Visual Function in X-Linked RP? ARVO Summer Eye Research Conference, Toward the Prevention of Age Related Macular Degeneration, Ft. Myers, FL, July 9-12, 2006.
 98. **Hoffman DR**, Wheaton DKH, Birch DG: Docosahexaenoic acid profiles in red blood cells of patients with retinal degenerative diseases. Invest. Ophthalmol. Vis. Sci., **48**: E-abstract 574, 2007.
 99. Scalabrin DM, **Hoffman D**, Harris C, Kineman B, Diersen-Schade D: Influence of Lactobacillus GG (LGG) supplementation of partially and extensively hydrolyzed formulas on infant long-chain polyunsaturated fatty acid (LCPUFA) status. European Academy of Allergology and Clinical Immunology, Barcelona, Spain, June 7-11, 2008.
 100. **Hoffman DR**, Castañeda YS, Garfield S, Ferguson P, Birch EE: Four-year neurodevelopmental outcomes following a randomized trial of long-chain polyunsaturated fatty acid (LCP) supplementation during the first 12 months of life. FASEB, San Diego, CA, April 5-8, 2008.
 101. Drover JR, **Hoffman DR**, Castañeda YS, Morale SE, Birch EE: Three randomized clinical trials of early long-chain polyunsaturated fatty acid supplementation on means-end problem solving in nine month-olds. International Society for the Study of Fatty Acids & Lipids, Kansas City, May 17-22, 2008.
 102. **Hoffman DR**, Carlson SE, Gustafson KM, Berseth CL, Marunycz JD, Birch EE: Preliminary data indicate that supplementing infant formula with 3 levels of docosahexaenoic acid (DHA) provides similar results in visual acuity at 12 months. International Society for the Study of Fatty Acids and Lipids, Kansas City, May 17-22, 2008.

103. Wheaton DHK, Koenekoop RK, Khan H, Takacs A, **Hoffman DR**: Evaluation of Olfactory Function in Patients with X-linked Retinitis Pigmentosa (xLRP) Due to Mutations in the Retinitis Pigmentosa GTPase Regulator Gene (RPGR). Invest. Ophthalmol. Vis. Sci., **50**: E-abstract 1000, 2009.
104. Clark K, Birch D, **Hoffman D**, Patel H, Daiger S, Bowne S, Sullivan L, Wheaton D: Assessment of Everyday Visual Tasks in Carriers of X-Linked Retinitis Pigmentosa: Use of the Visual Activities and Low Luminance Questionnaires. Invest. Ophthalmol. Vis. Sci., **51**: E-abstract 949, 2010.
105. SanGiovanni JP, Aderman CM, Rojas C, Clemons TE, Chew E, Uauy R, **Hoffman DR**, Smith LE: Integrated Systems Approach to Study the Role of Omega-3 Long-Chain Polyunsaturated Fatty Acids in Health and Disease of the Retina. Invest. Ophthalmol. Vis. Sci. **51**: E-Abstract 2774, 2010.
106. **Hoffman DR**, Drover J, Castañeda YS, Morale S, Garfield S, Wheaton D, Birch E. Cognitive function in 18-month-old term infants of the DIAMOND study: A DHA dose-response randomized, controlled clinical trial. International Society for the Study of Fatty Acids & Lipids, Maastricht, Netherlands, May 31, 2010.
107. SanGiovanni JP, Aderman CM, Rojas C, Clemons TE, Chew EY, Uauy R, **Hoffman DR**, Smith LEH: Integrated systems approach to study ω -3 long-chain polyunsaturated fatty acids in health and disease of the neural and vascular retina. International Society for the Study of Fatty Acids & Lipids, Maastricht, Netherlands, May 31, 2010.
108. Hughbanks-Wheaton, D, Kimberling W, Jensen M, **Hoffman D**. Omega-3 fatty acid dietary intake and red blood cell (RBC) docosahexaenoic acid (DHA) levels in Usher Syndrome subtypes. International Symposium on Usher Syndrome and Related Diseases, Valencia, Spain, May 27-29, 2010.
109. Locke, KG, Locke KI, Wen Y, Hood DC, **Hoffman DR**, Birch DG. FdOCT measures of progression over a one year interval in patients with X-linked retinitis pigmentosa (XLRP). Invest. Ophthalmol. Vis. Sci. **52**: E-Abstract 4986, 2011.
110. Webb KD, Patel HM, Bowne SJ, Sullivan LS, Fahim AT, Daiger SP, **Hoffman DR**, Birch DG, Wheaton DK. Assessment of phenotypic variability among female carriers of x-linked retinitis pigmentosa (xLRP) due to RPGR mutations. Invest. Ophthalmol. Vis. Sci. **52**: E-Abstract 5386, 2011.

INVITED TALKS (2005-2011):

1. **Hoffman DR**. A Randomized, Placebo-Controlled Clinical Trial of Docosahexaenoic Acid (DHA) Supplementation for X-Linked Retinitis Pigmentosa (XLRP) Phase II. Annual meeting of the Southwest Regional Foundation Fighting Blindness Center, Dallas, TX April 1, 2005.
2. **Hoffman DR**, Locke KG, Wheaton DKH, Fish GE, Spencer R and Birch DG: Can DHA supplementation slow the loss of visual function in X-linked RP? ARVO Summer Eye Research Conference, Toward the Prevention of Age Related Macular Degeneration, Ft. Myers, FL, July 9-12, 2006.
3. **Hoffman DR**, "New Discoveries: The Impact of DHA and ARA Levels on Developmental Outcomes from Newborns to Toddlers". Health Care

- Professionals Symposium, Bali, Indonesia, sponsored by Mead Johnson Indonesia, March 10, 2007.
4. **Hoffman DR**, "New Discoveries: The Impact of DHA and ARA Levels on Developmental Outcomes from Newborns to Toddlers". Health Care Professionals Symposium, Bangkok, Thailand, sponsored by Mead Johnson Thailand, March 13, 2007.
 5. **Hoffman DR**, "New Discoveries: The Impact of DHA and ARA Levels on Developmental Outcomes from Newborns to Toddlers". Thai Nutrition Clinical Society, Chiang Mai, Thailand, sponsored by Mead Johnson Thailand, March 15, 2007.
 6. **Hoffman DR**, "New Discoveries: The Impact of DHA and ARA Levels on Developmental Outcomes from Newborns to Toddlers". Vietnamese Ministry of Health, Hanoi, Vietnam, sponsored by Mead Johnson Vietnam, March 16, 2007.
 7. **Hoffman DR**, "New Discoveries: The Impact of DHA and ARA Levels on Developmental Outcomes from Newborns to Toddlers". Health Care Professionals Symposium, Ho Chi Minh City, Vietnam, sponsored by Mead Johnson Vietnam, March 18, 2007.
 8. **Hoffman DR**. "The Functional Impact of Long-chain Polyunsaturated Fatty Acids on Infant Development" Grand Forks Human Nutrition Research Center, United States Department of Agriculture, Grand Forks, ND, April 10, 2007.
 9. **Hoffman DR**, "New Discoveries: The Impact of DHA and ARA Levels on Developmental Outcomes from Newborns to Toddlers". Health Care Professionals Symposium, Taipei, Taiwan, sponsored by Mead Johnson & Company, June 30, 2007.
 10. **Hoffman DR**, "New Discoveries: The Impact of DHA and ARA Levels on Developmental Outcomes from Newborns to Toddlers". Health Care Professionals Symposium, Taichung, Taiwan, sponsored by Mead Johnson & Company, July 1, 2007.
 11. **Hoffman DR**, "New Discoveries: The Impact of DHA and ARA Levels on Developmental Outcomes from Newborns to Toddlers". Health Care Professionals Symposium, Kaohsiung, Taiwan, sponsored by Mead Johnson & Company, July 2, 2007.
 12. **Hoffman DR**. "New Discoveries: The Impact of DHA and ARA Levels on Developmental Outcomes from Newborns to Toddlers" The Obstetrical and Gynaecological Society of Hong Kong, Hong Kong, China, June 29, 2007.
 13. **Hoffman DR**. "The Functional Impact of Supplementing Long-chain Polyunsaturated Fatty Acids into Infant Formula" Mastering Metabolic Therapy, Nutricia North America, Las Vegas, NV, October 15-17, 2007.
 14. **Hoffman DR**. "Recent Evidence that Dietary Supply of DHA and ARA in Early Infancy Leads to Positive Trends in IQ of 4-year-olds" The 13th Congress of The Asean Pediatric Federation and the 45th Annual Convention of The Philippine Pediatric Society Joint Meeting, Manila, Philippines, April 14, 2008.
 15. **Hoffman DR**. "Recent Evidence that Dietary Supply of DHA and ARA in Early Infancy Leads to Positive Trends in IQ of 4-year-olds" Health Care Professionals Symposium, Singapore, Singapore, sponsored by Mead Johnson & Company, April 18, 2008.

16. **Hoffman DR.** "Recent Evidence that Dietary Supply of DHA and ARA in Early Infancy Leads to Positive Trends in IQ of 4-year-olds" *Health Care Professionals Symposium, Kuala Lumpur, Malaysia, sponsored by Mead Johnson & Company, April 19, 2008.*
17. **Hoffman DR.** "Optimizing Vision and Cognition in Term Infants By Dietary DHA+ARA Supplementation" Workshop on DHA as a Required Nutrient, Baltimore, MD, June 20-21, 2008.
18. **Hoffman DR.** "Inherited Retinal Degeneration and Nutrition: The Science Behind the Headlines" Foundation Fighting Blindness Visions 2008, Washington, DC, August 8-10, 2008.
19. **Hoffman DR.** "What's Cooking for Your Retina: A Culinary Demonstration" Foundation Fighting Blindness Visions 2008, Washington, DC, August 8-10, 2008.
20. **Hoffman DR,** "Update of High-Dose DHA Supplementation in Early Stage X-linked Retinitis Pigmentosa: A Placebo-Controlled Clinical Trial". The Foundation Fighting Blindness Southwest Regional Research Center for the Study of Degenerative Retinal Diseases, Dallas, TX, Oct. 9, 2009.